Text Larger Text Smaller

Text Size

Print Page Print


i Zoledronate is an IV bisphosphonate that reduces risk of hip, vertebral and non-vertebral fractures6. In the pivotal clinical trials, zoledronate was administered annually for three years. However, zoledronate’s duration of action is considerably longer than one year; therefore, it is common practice to administer the three initial doses at intervals of 18 or 24 months.